Kairos Pharma, Ltd. (KAPA) 10-Year Financial Performance & Capital Metrics

KAPA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutKairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.Show more

Revenue $0
EBITDA -$2M -40.5%
Net Income -$3M -43.7%
EPS (Diluted) -0.23 -35.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -192.96%
ROIC -178.31%
Debt/Equity -
Interest Coverage -2.73 +84.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-84.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM-18.38%

ROCE

10Y Avg-123.84%

5Y Avg-123.84%

3Y Avg-123.84%

Latest-123.84%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	98K	160K	160K	160K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	-98K	-160K	-160K	-160K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-0.63%	0%	0%
Operating Expenses+	1.05M	1.84M	411K	1.55M	2.18M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	1.03M	1.66M	324K	1.47M	1.77M
SG&A % of Revenue	-	-	-	-	-
Research & Development	20K	183K	87K	82K	414K
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-1.05M	-1.94M	-571K	-1.71M	-2.34M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-0.86%	0.71%	-2%	-0.37%
EBITDA+	-1.05M	-1.84M	-411K	-1.55M	-2.18M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-0.76%	0.78%	-2.78%	-0.4%
D&A (Non-Cash Add-back)	0	98K	160K	160K	160K
EBIT	-1.05M	-1.94M	-571K	-1.71M	-1.74M
Net Interest Income+	-5.41K	-202K	-479K	-98K	-859K
Interest Income	0	0	0	0	0
Interest Expense	5.41K	202K	479K	98K	859K
Other Income/Expense	-5.41K	-202K	-479K	-98K	-260K
Pretax Income+	-1.05M	-2.15M	-1.05M	-1.81M	-2.6M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-1.05M	-2.15M	-1.05M	-1.81M	-2.6M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1.04%	0.51%	-0.73%	-0.44%
Net Income (Continuing)	-1.05M	-2.15M	-1.05M	-1.81M	-2.6M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.09	-0.17	-0.10	-0.17	-0.23
EPS Growth %	-	-0.81%	0.41%	-0.7%	-0.35%
EPS (Basic)	-0.09	-0.17	-0.10	-0.17	-0.23
Diluted Shares Outstanding	11.22M	12.84M	10.24M	10.38M	11.36M
Basic Shares Outstanding	11.22M	12.84M	10.24M	10.38M	11.36M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.31K	73K	437K	101K	4.17M
Cash & Short-Term Investments	14.31K	73K	437K	93K	1.27M
Cash Only	14.31K	73K	437K	93K	1.27M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	0	8K	38K
Total Non-Current Assets+	0	702K	599K	864K	2.05M
Property, Plant & Equipment	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	702K	542K	382K	222K
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	0	57K	482K	1.38M
Total Assets+	14.31K	775K	1.04M	965K	6.22M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	53.17%	0.34%	-0.07%	5.44%
Total Current Liabilities+	357.15K	1.94M	1.63M	2.4M	992K
Accounts Payable	307.15K	1.55M	1.63M	2.4M	0
Days Payables Outstanding	-	5.77K	3.72K	5.48K	-
Short-Term Debt	50K	380K	4K	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	14K	0	0	992K
Current Ratio	0.04x	0.04x	0.27x	0.04x	4.20x
Quick Ratio	0.04x	0.04x	0.27x	0.04x	4.20x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	0	582K	638K	448K
Long-Term Debt	0	0	582K	638K	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	448K
Other Non-Current Liabilities	0	0	0	0	0
Total Liabilities	357.15K	1.94M	2.21M	3.04M	1.44M
Total Debt+	50K	380K	586K	638K	0
Net Debt	35.69K	307K	149K	545K	-1.27M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-193.30x	-9.62x	-1.19x	-17.49x	-2.73x
Total Equity+	-342.84K	-1.17M	-1.18M	-2.08M	4.78M
Equity Growth %	-	-2.4%	-0.01%	-0.76%	3.3%
Book Value per Share	-0.03	-0.09	-0.12	-0.20	0.42
Total Shareholders' Equity	-342.84K	-1.17M	-1.18M	-2.08M	4.78M
Common Stock	192.39K	10K	10K	11K	14K
Retained Earnings	-1.2M	-3.35M	-4.4M	-6.21M	-8.81M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38.53K	-412K	-353K	81K	-3.96M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-9.69%	0.14%	1.23%	-49.83%
Net Income	-1.05M	-2.15M	-1.05M	-1.81M	-2.6M
Depreciation & Amortization	0	98K	160K	160K	160K
Stock-Based Compensation	800K	300K	0	913K	218K
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	144K	408K	56K	254K
Working Capital Changes	212.82K	1.19M	129K	764K	-1.98M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	0	0
Cash from Investing+	0	-109K	0	0	0
Capital Expenditures	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	37K	580K	717K	-425K	5.13M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-13K	0	-121K	0	-390K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-38.53K	-412K	-353K	81K	-3.96M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-9.69%	0.14%	1.23%	-49.83%
FCF per Share	-0.00	-0.03	-0.03	0.01	-0.35
FCF Conversion (FCF/Net Income)	0.04x	0.19x	0.34x	-0.04x	1.52x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-192.96%
Return on Invested Capital (ROIC)	-	-	-	-	-178.31%
Interest Coverage	-193.30x	-9.62x	-1.19x	-17.49x	-2.73x
FCF Conversion	0.04x	0.19x	0.34x	-0.04x	1.52x

Frequently Asked Questions

Growth & Financials

Kairos Pharma, Ltd. (KAPA) grew revenue by 0.0% over the past year. Growth has been modest.

Kairos Pharma, Ltd. (KAPA) reported a net loss of $5.1M for fiscal year 2024.

Dividend & Returns

Kairos Pharma, Ltd. (KAPA) has a return on equity (ROE) of -193.0%. Negative ROE indicates the company is unprofitable.

Kairos Pharma, Ltd. (KAPA) had negative free cash flow of $3.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener